Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Association between the interferon-induced transmembrane protein 3 gene (IFITM3) rs34481144 / rs12252 haplotypes and COVID-19

Elías Cuesta-Llavona, Guillermo M. Albaiceta, Marta García-Clemente, Israel D. Duarte-Herrera, Laura Amado-Rodríguez, Tamara Hermida-Valverde, Ana I. Enríquez-Rodríguez, Cristina Hernández-González, Santiago Melón, Marta E. Álvarez-Argüelles, José A. Boga, Susana Rojo-Alba, Daniel Vázquez-Coto, Juan Gómez, Eliecer Coto, PhD

Genética Molecular, Hospital Universitario Central Asturias, Oviedo, Spain
Unidad de Cuidados Intensivos Cardiológicos, Hospital Universitario Central Asturias, Oviedo, Spain
Neumología, Hospital Universitario Central Asturias, Oviedo, Spain
Microbiología, Hospital Universitario Central Asturias, Oviedo, Spain
Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Oviedo, Spain
Universidad de Oviedo, Oviedo, Spain
CIBER-Enfermedades Respiratorias. Instituto de Salud Carlos III. Madrid, Spain
Instituto Universitario de Oncología del Principado de Asturias. Oviedo, Spain

ARTICLE INFO
Keywords: Interferon induced transmembrane proteins IFIT3 Gene variant COVID-19 Genetic association

ABSTRACT
The interferon induced transmembrane-protein 3 (IFITM3) plays an important role in the defence against viral infection. IFITM3 gene variants have been linked to differences in expression and associated with the risk of severe influenza by some authors. More recently, these variants have been associated with the risk of COVID-19 after SARS-CoV-2 infection. We determined the effect of two common IFITM3 polymorphisms (rs34481144 C/T and rs12252 A/G) on the risk of hospitalization due to COVID-19 by comparing 484 patients (152 required support in the intensive care unit, ICU) and 182 age and sex matched controls (no disease symptoms). We found significantly higher frequencies of rs34481144 T and rs12252 G carriers among the patients (OR = 2.02 and OR = 1.51, respectively). None of the two variants were associated with ICU-admission or death. We found a significantly higher frequency of rs34481144 CC + rs12252 AA genotype carriers among the controls, suggesting a protective effect (p = 0.001, OR = 0.56, 95%CI = 0.40–0.80). Moreover, haplotype rs34481144 C - rs12252 A was significantly increased in the controls (p = 0.008, OR = 0.71, 95%CI = 0.55–0.91).

Our results showed a significant effect of the IFITM3 variants in the risk for hospitalization after SARS-CoV-2 infection.

1. Introduction
The human interferon-induced transmembrane proteins (IFITMs) are a family of small proteins with five members, three of them (IFITM1-3) with a role in the innate immunity against microorganism infection (Smith et al., 2014; Liao et al., 2019; Zhao et al., 2019; Ren et al., 2020). IFITMs localize at the plasmatic and cell-vesicle membranes (Bailey et al., 2014), and block the fusion of enveloped-viruses with the cell membranes (Weidner et al., 2010; Perreira et al., 2013; Compton et al., 2014; Desai et al., 2014; Smith et al., 2019; Suddala et al., 2019). These proteins contain an amphipathic helix domain that would alter the cell lipid membrane disfavouring virus fusion (Li et al., 2013; Cesarino et al., 2017; Suddala et al., 2019).

IFITMs play a role in the response to coronavirus (CoV) mainly as inhibitors of infection (Huang et al., 2011; Wrensch et al., 2014; Zheng et al., 2020), although they could also enhance CoV infections (Zhao et al., 2014; Compton et al., 2014; Desai et al., 2014; Smith et al., 2019; Suddala et al., 2019).
et al., 2014, 2018). In the case of IFITM3 the capacity to inhibit or enhance SARS-CoV or MERS-CoV infection seems to depend on the localization in the plasma membrane (increased infection) or in the endosomal membrane (reduced infection) (Zhao et al., 2018). Interestingly, polymorphisms in the IFITM3 genes that determine differences in the plasma membrane localization would affect the susceptibility to viral infection (Everitt et al., 2012; Zhao et al., 2018).

Due to their role in infection, variants in the IFITM genes are candidates to modify the risk for viral infection and disease severity (Zhao et al., 2019). Two IFITM3 single nucleotide polymorphisms (SNPs) have been well characterised, rs12252 and rs34481144. SNP rs12252 A/G has been associated with the risk of severe influenza by some authors but not others, and the functional mechanism remains controversial (Chen et al., 2018; Prabhu et al., 2018; Qin et al., 2018; Martins et al., 2020). The G allele was described as a risk factor for the severity of disease after avian and H1N1/09 infection (Zhang et al., 2013). The GG homozygotes showed a lower rate of seroconversion after trivalent vaccination with inactivated viruses (Lei et al., 2020). These authors reported that healthy adult volunteers with the rs12252 C/C genotype showed lower specific antibodies against H1N1, H3N2 and B viruses compared to rs12252 A-carriers. Moreover, IFITM3 deletion mice (Ifitm3−/−) showed lower total IgG against these viruses compared to wild type littermates. The authors concluded that the genetic mechanisms linked to IFITM3 reduction might attenuate the antibody response against influenza, increasing the risk of adverse events in infected (Lei et al., 2020).

The IFITM3 rs12252 G was also associated with the progression of HIV-1 infection toward reduced CD4+ T-cells count (Zhang et al., 2015). This SNP was linked to an alternative splicing of the transcript that could result in truncated and altered localization of the IFITM3, but this effect was not confirmed by some authors (Everitt et al., 2012; Allen et al., 2017; Randolph et al., 2017). SNP rs34481144 C/T is in the 5’ UTR of the gene and the T allele has been associated with an increased risk of severe influenza (Allen et al., 2017). The underlying mechanism seems to be an impaired binding of transcription factors to the promoter with the T allele, that would result in a reduced mRNA expression compared to the C allele. Furthermore, the change C > T would disrupt a methylation site and T-carriers had reduced CD8 T-cells in their airways during natural influenza infection. IFITM3 would promote the accumulation of airway CD8 T-cells at mucosal sites, and a reduction of the expression might result in lower CD8 levels in the airways and increased risk for severe influenza (Allen et al., 2017).

In reference to SARS-CoV-2 the effect of IFITMs on infection remains unclear but might depend on the cellular localization, as reported for IFITM3 in mouse and humans. A recent study with IFITM3 mutants identified amino acids with pro- and anti-viral effects in terms of distinct cellular locations and mechanisms of action (Shi et al., 2021). The expression of IFITMs in human lung cells would facilitate the SARS-CoV-2 infection, in a mechanism that could involve the interaction between the spike (S) viral protein and IFITMs (Prelli Bozzo et al., 2021). Moreover, the entry and replication of SARS-CoV-2 into several cell types was inhibited by IFITM-derived peptides and targeting antibodies. In agreement with this role in infection, variants in the IFITM3 gene have been associated with the clinical outcomes after SARS-CoV-2 infection (COVID-19). Most of the studies analysed the rs12252 SNP and concluded an association between the G allele and disease severity or a lack of association, but were based on small sizes that impair the statistical power (Zhang et al., 2020; Schönfelder et al., 2021; Gómez et al., 2021; Alghamdi et al., 2021).

Our aim was to determine the association between IFITM3 rs34481144 and rs12252 SNPs and haplotypes and severe COVID-19. For this purpose we compared patients with pneumonia that required hospitalization and population controls without symptoms of SARS-CoV-2 infection. We also compared patients who required or not admission in the Intensive Care Unit (ICU), and the effect of these gene variants in the risk of death due to COVID-19.

### 2. Methods

We studied 484 COVID-19 patients hospitalised in the period March–December 2020 due severe pneumonia and positive for SARS-CoV-2 in a PCR-test. Of these, 152 needed critical care support (ICU) with high-flow oxygen, positive-pressure ventilation or vasoactive drugs. The controls were 182 individuals aged 55 years or older without disease symptoms. These controls were negative for SARS-CoV-2 infection with a serological test. Patients and controls were of European ancestry from the region of Asturias, Northern Spain (total population approx 1 million), and gave their informed consent to participate in the study approved by the Ethical Committee of Medical Research of Asturias.

We isolated the DNA from blood-leukocytes from all the patients and controls. The IFITM3 rs34481144 C/T and rs12252 A/G SNPs were genotyped by real-time PCR with Taqman probes (Fisher Scientific, assays id. C_26288451_10 and C_175677529_10). The method was validated by sequencing DNA samples representing the three genotypes of the two SNPs. These nucleotide changes are defined according to either the genomic coding (plus) or the cDNA strands. In this work the two SNPs were named according to the standard Human Genome Variation Society guidelines, rs34481144 C/T (c.-23 G > A) and rs12252 A/G (c.42T > C, p.Ser14Cys).

To confirm the adjustment of the observed genotype frequencies to the Hardy-Weinberg equilibrium we used an online programme (https://wpcalc.com/en/equilibrium-hardy-weinberg). The statistical analysis was performed with the r-program (www.r-project.org). The linear regression was used to compare the frequencies between the groups, and multiple logistic regression (linear generalised model, LGM) to determine the association between COVID-19 severity and sex, age, hypertension, and the rs34481144 and rs12252 variants. For all the comparisons we considered a p value < 0.05 as statistically significant, and Odds ratios (OR) and 95% confidence intervals (CI) were also calculated. Their statistical power was calculated online (https://clincalc.com/stat/samplesize.aspx).

#### 3. Results and discussion

In Table 1 we summarised the main values in COVID-19 patients and healthy controls. Hospitalization with ICU admission was associated with

| Table 1 | Main values in the COVID-19 patients and healthy sex and age matched controls (individuals without COVID-19 symptoms). |
|---------|------------------------------------------------------------------------------------------------------------------|
|         | **COVID19** | **CONTROLS** | **ICU** | **No-ICU** |
| N        | N = 484 | N = 182 | N = 152 | N = 332 |
| Male     | 276 (57%) | 93 (51%) | 113 (74%) | 198 (59%) |
| Mean age, years | 66 ± 16 | 67 ± 11 | 67 ± 16 | 64 ± 16 |
| Interaquartile range, years | 55–75 | 70–76 | 60–76 | 52–75 |
| Hypertension | 224 (46%) | 49 (27%) | 88 (58%) | 136 (41%) |
| Death   | 45 (9%) | – | 38 (24%) | 7 (2%) |
| rs34481144 C/T | | | | |
| CC      | 181 (37%) | 84 (46%) | 61 (40%) | 120 (36%) |
| CT      | 235 (49%) | 80 (44%) | 69 (46%) | 166 (50%) |
| TT      | 68 (14%) | 18 (10%) | 22 (14%) | 46 (14%) |
| TT + CT vs CC | p = 0.04; OR = 1.43; 95% CI = 1.02–2.03 | | | |
| T-frequency | 371 (0.38) | 116 (0.32) | 113 (0.37) | 258 (0.39) |
| T vs C | p = 0.03; OR = 1.33; 95% CI = 1.03–1.72 | | | |
| rs12252 A/G | | | | |
| AA      | 433 (89%) | 172 (92%) | 133 (88%) | 300 (90%) |
| AG      | 47 (10%) | 10 (8%) | 17 (11%) | 30 (9%) |
| GG      | 4 (1%) | 0 | 2 (1%) | 2 (1%) |
| AG + GG vs AA | p = 0.04; OR = 2.02; 95% CI = 1.01–4.08 | | | |
| G-frequency | 55 (0.06) | 14 (0.03) | 14 (0.07) | 34 (0.05) |
| p < 0.18; OR = 1.51; 95% CI = 0.83–2.74 | | | |
male sex ($p = 0.01$), advanced age ($p = 0.0002$), and hypertension ($p = 0.0006$), but not with the IFITM3 SNPs (Table 1). Compared to healthy age and sex matched controls, COVID-19 hospitalization was increased among carriers of rs34481144 T-genotypes ($p = 0.04; \text{OR} = 1.43; 95\% \text{CI} = 1.02 – 2.03$) and rs12252 G-genotypes ($p = 0.04; \text{OR} = 2.02; 95\% \text{CI} = 1.01–4.08$). The frequency of deaths was significantly higher in the ICU patients (24% vs 2%). The risk of death among the ICU patients was associated with advanced age ($p = 0.04; \text{OR} = 1.04, 95\% \text{CI} = 1.01–1.08$), but not with male sex or the IFITM3 SNPs (Table 2). There was a higher frequency of hypertensives among the death cases, without statistical significance ($p = 0.25$). Because there were only 7 deaths among the no-ICU patients we did not compare the studied variables between deceased and not in the no-ICU group.

According to our results the rs34481144 T was associated with an increased risk of severe COVID-19 in need of hospitalization. The reported frequency among Spanish (accessed at LD-Link, https://ldlink.nci.nih.gov/?tab=home) was $T = 0.40$, similar to the frequency among our patients but higher than in the healthy controls (Fig. 1). This supported the finding that carriers of the rs34481144 T were at increased risk of COVID-19, with the CC as a protective. Similarly, the rs12252 G showed a higher frequency among the patients (0.06) compared to the Spanish (0.03) and the healthy controls (0.03). For this variant the AA genotype might be protective.

Our study was based on a limited size, and we thus calculated the required size to reach a statistical power of 80 at a $p = 0.05$. For a case-control study comparing patients with healthy controls the post-hoc power was 57% for the rs34481144 T-carriers. For a power of 80 at least 500 healthy subjects should be genotyped.

We determined the association between the rs34481144 - rs12252 haplotypes and the risk of hospitalization due to COVID-19 (suppl. Table 1). Haplotype C-A was decreased in the patients compared to controls (57% vs 64%), with a significant protective effect: $p = 0.04, \text{OR} = 0.72, 95\% \text{CI} = 0.53–0.98$ (Fig. 2). The haplotype distribution in our population was consistent with the reported in the human genome database (https://ldlink.nci.nih.gov), with the rs34481144 C/C genotype (protective) always inherited (in complete linkage disequilibrium) with rs12252 G/G (risk genotype). The rs12252 A was inherited with either rs34481144 C or T, indicating that the risk alleles were inherited on opposite haplotypes. This finding was in agreement with the reported effect among severe influenza patients, where the risk allele of rs34481144 was inherited with the protective allele of rs12252 suggesting that these IFITM3 variants provided non-overlapping risks (Allen et al., 2017). Of note, the CA haplotype was more common among the

### Table 2: Main values in the ICU patients according to death.

|                  | Death ($N = 38$) | No-death ($N = 114$) |
|------------------|-----------------|----------------------|
| Age range        | 33-64           | 32-64                |
| Mean age         | 66.79 ± 11.84   | 64.54 ± 10.58        |
| Male             | 28 (74%)        | 85 (75%)             |
| Hypertension     | 25 (66%)        | 63 (35%)             |
| rs34481144 C/T   |                 |                      |
| CC, 61           | 18 (47%)        | 43 (38%)             |
| CT, 69           | 14 (37%)        | 55 (48%)             |
| TT, 22           | 6 (16%)         | 16 (14%)             |
| T-frequency      | 26 (0.34)       | 87 (0.38)            |
| rs12252 A/G      |                 |                      |
| AA, 133          | 32 (86%)        | 101 (88%)            |
| AG, 17           | 5 (14%)         | 12 (11%)             |
| GG, 2            | 1 (0)           | 1 (1%)               |
| G-frequency      | 0.07            | 0.07                 |

Fig. 1. Reported frequencies of the IFITM3 variants in populations worldwide. Data accessed at the ensemble web (www.ensembl.org).
Afr: Africans, Amr: Americans, EAS: East-Asians, EUR: Europeans, SAS: South-Asians; CEU: Utah residents of European ancestry, FIN: Finns, GBR: Great Britain Caucasians, IBS: Spanish, TSI: Toscany.
These candidate variants are in the genes that encode proteins of the viral diseases, such as in pandemic influenza (et al., 2021). Several authors have studied the association between ICU than in no-ICU patients (33% vs 29%; p = 0.001, OR = 0.56). This genotype combination was non-significant in the controls compared to COVID-19 hospitalized patients: p = 0.001, OR = 0.56 (95%CI = 0.40–0.80).

Individuals double homozygotes CC-AA were more frequent in the controls (33% vs 29%; p = 0.008, OR = 0.71, 95%CI = 0.55–0.91). The raw numbers are presented in the supplementary file.

The clinical course of the SARS-CoV-2 infection is heterogeneous, ranging from individuals who remained asymptomatic to severe COVID-19 with bilateral pneumonia and hospitalization. The most severe cases require attention in the ICU and are at a high risk of death. The variable manifestation depends on several factors, being advanced age, male gender, and hypertension and other preexisting cardiovascular complications well recognised risk factors for disease severity and mortality. Besides, a genetic predisposition has been reported and several loci have been associated with the risk of severe COVID-19 (Fricke-Galindo, 2021). In particular, the chromosome 3 chemokine-receptor gene cluster has been replicated in several studies, and there is also a strong evidence for a protective role among individuals with the O blood group and an increased risk for the A-group (Ellinghaus et al., 2021; Pairo-Castineira et al., 2021). Several authors have studied the association between COVID-19 and gene variants previously reported as risk factors for other viral diseases, such as influenza or HIV (Zhang et al., 2015). Many of these candidate variants are in the genes that encode proteins of the innate immunity, such as the IFITM3.

Everitt et found a statistically significant higher number of seasonal or pandemic influenza H1N1/09 hospitalized subjects with the minor IFITM3 rs12252-G allele (Everitt et al., 2012). The study was based on only 53 patients, but the authors provided evidence that the GG genotype reduced the influenza virus restriction in vitro. Zhang et al. also found a significant increased frequency of the GG genotype among patients with severe compared to mild influenza-disease, but the study was based on only 32 and 51 cases, respectively (Zhang et al., 2013). Mills et al. compared rs12252 genotypes in 34 patients with H1N1 influenza and severe pneumoniasa >5000 individuals with community-acquired mild lower respiratory tract infection and matched controls, and found an association between GG homozygotes and susceptibility to mild influenza but did not confirm the association with severe H1N1 infection (Mills et al., 2014). Gaio et al. compared 312 influenza patients with 624 matched non-hospitalized controls and found that GA/GG carriers had a higher risk of being hospitalized than AA patients (OR = 2.54, 95%CI = 1.54–4.19) (Gaio et al., 2016). Lopez Rodríguez et al. did not find a significant association between rs12252 and influenza virus infection (n = 148) or hospitalization due to influenza pneumonia (n = 60). The study compared these patients with 246 healthy Spanish individuals (Lopez-Rodriguez et al., 2016). Interestingly, there were no GG homozygotes in the control group, and the rare G allele was more common in the patients with the highest frequency among the ICU-patients (n = 34).

In a multicenter study with 275 cases of avian (H7N9) and pandemic (H1N1pdm09) influenza Lee et al. found an over-representation of rs12252 GG homozygotes among the patients compared to population controls (54.5% vs 33.2%; p = 0.02) (Lee et al., 2017).

Randolph et al. did not find a significant association between rs12252 and influenza infection in children (n = 358), and this variant was not associated with critical illness severity. These authors did not find alternative IFITM3 transcripts in the rs12252 genotypes, and this SNP was not associated with IFITM3 expression levels (Randolph et al., 2017). Interestingly, in this study the rs34481144 CC genotype was significantly more frequent in the controls, suggesting a protective effect against influenza infection. In addition to the above referenced studies the association between rs12252 GG and influenza has been confirmed by some authors (Pan et al., 2017) but not others (Carter et al., 2018).

Few studies have addressed other IFITM3 SNPs in influenza. The most relevant study reported a significant association between the rs34481144 T allele and disease severity, that was linked to reduced IFITM3 expression compared to the C-allele (Allen et al., 2017). These authors also found that influenza-infected carriers of the A (risk) allele had reduced CD8 T-cells in their airways, that was in agreement with a IFITM3 expression of CD8 T-cell accumulation. IFITM3 could thus have an important role in promoting the persistence of immune cells at mucosal sites, and IFITM3 functional variants could thus contribute to the risk of viral infection and disease severity. Interestingly, the T risk allele was absent in East Asian populations, and its effect on influenza and other viral diseases cannot thus be evaluated in these population groups.

In reference to SARS-CoV-2 infection and COVID-19 severity, to the best of our knowledge only the nest studies have addressed the association with IFITM3 SNPs. Zhang et al. compared 56 mild and 24 severe COVID-19 patients and found a higher frequency of the GG homozygotes among the severe cases (Zhanget al., 2020). In a study involving 880 Saudi patients, Alghamdi et al. found that rs12252-G was associated with hospital admission (OR = 1.65; 95% CI = 1.01–2.70) and mortality (OR = 2.2; 95% CI = 1.16–4.20) (Alghamdi et al., 2021). Our group also found a significantly higher frequency of the rs12252-G among COVID-19 patients who required hospitalization (n = 288) during the first SARS-CoV-2 wave (March to mid-April 2020) compared to sex matched population controls (n = 440) (Gomez et al., 2021). These SNP did not differ between patients who required ICU or not. Schönfelder et al. did not find association between rs12252 or rs34481144 and SARS-CoV-2 infection risk or severity of COVID-19 in a German cohort (239 patients and 253 controls) (Schönfelder et al., 2021). However, these authors found the rs12252 GG genotype in two SARS-CoV-2-positive patients and none of the controls, and the study was thus underpowered to evaluate the association with genotype. They also
found a non-significant higher frequency of rs34481144 T-allele in the patients who require hospitalization (severe cases, n = 75). Unfortunately, these authors did not analyse the association with the rs12252 - rs34481144 haplotypes.

**Study limitations.** Our study has several limitations. First, it was based on a limited number of patients and controls, that reduced the statistical power. Second, we compared patients with severe COVID-19 who required hospitalization and healthy individuals without symptoms of SARS-CoV-2 infection. The association between IFITM3 and mild disease was not evaluated in our study. It is thus possible that these variants are associated with an overall risk for infection rather than with disease severity. However, we have previously reported the rs12252 G frequency among elderly population controls (n = 440) recruited before the SARS-CoV-2 pandemic. The risk G allele had the same frequency (0.03) than in the SARS-CoV-2 asymptomatics, suggesting a non-significant effect on the risk of viral infection (Gómez et al., 2021).

More studies to clarify these issues are necessary.

**Conclusions.** Carriers of the rs34481144 T and rs12252 G were significantly more frequent in COVID-19 patients who required hospitalization and healthy individuals without symptoms of SARS-CoV-2 infection. The rs34481144 C - rs12252 A haplotype, previously associated with risk of severe in

---

**Contributorship**

All the authors contributed to this work by recruiting the patients and performing the genetic and statistical analysis. All the authors approved the submission of this manuscript.

**Writing original draft and review:** E.C., J.G., G.M.A.

**Conceptualization:** E.C., J.G., G.M.A.

**Statistical analysis:** E.C.

**Supervision:** J.G., G.M.A., E.C.

**Genetic analysis:** E.C., J.G., IDH, SM, MEAA, JAB, SRA

**Other authors:** patients data acquisition

**Funding information**

No external funding was received for this work.

**Data accessibility**

The full raw data are available as excel files upon request to the corresponding authors.

**Declaration of competing interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.crvio.2021.100016.

**References**

Alghamdi, J., Alaamery, M., Barhoumi, T., Rashid, M., Alajmi, H., Aljasser, N., et al., 2021. Jul. Interferon-induced transmembrane protein-3 genetic variant rs12252 is associated with COVID-19 mortality. Genomics 113 (4), 1733–1741. https://doi.org/10.1016/j.ygeno.2021.04.002, 33836280.

Allen, E.K., Randolph, A.G., Bhanage, T., Dogra, P., Olsson, M., Oshamsky, C.M., et al., 2017. Aug. SNP-mediated disruption of CTGF binding to the IFITM3 promoter is associated with risk of severe influenza in humans. Nat. Med. 23 (8), 975–983. https://doi.org/10.1038/nm.4370, 28714988.

Bailey, G., Li, N., Zhang, G., Huang, C., 2014 Nov 1. IFITM3-family proteins: the cell’s first line of antiviral defense. Ann Rev Virol 1, 261–283. https://doi.org/10.1146/annurev-virology-013114-122545.

Carter, T.C., Hebring, E.J., Liu, J., Mosley, J.D., Shaffer, C.M., Iavicci,C., et al., 2018 Mar. Pilot screening study of targeted genetic polymorphisms for association with seasonality of influenza hospital admission. J. Med. Virol. 90 (3), 436–446. https://doi.org/10.1002/jmv.24975. Epinol 21 (7), 29053189.

Chen, T., Xiao, M., Yang, J., Chen, X.Y., Bai, T., Tang, Y., Shen, Y.L., 2018 Nov 13. Association between rs12252 and influenza susceptibility and severity: an updated meta-analysis. Epidemiol. Infect. 147, e99. https://doi.org/10.1017/S0950268818002832, 34021689.

Chen, N.M., Compton, A.K., McMichael, T.M., Kenney, A.D., Zhang, L., Soervana, V., et al., 2017 Oct. IFITM3 requires an amphipathic helix for antiviral activity. EMBO Rep. 18 (10), 1740–1751. https://doi.org/10.15252/embor.201744100, 28835547.

Compton, A.A., Bruel, T., Porrot, F., Mallet, A., Sachse, M., Euvrard, M., et al., 2014 Dec 1. IFITMs restrict the replication of multiple pathogenic viruses. J. Mol. Biol. 425 (24), 4937–4955. https://doi.org/10.1016/j.jmb.2013.09.024, 24076421.

Martins, J.S.C., Oliveira, M.L.A., Garcia, C.C., Siqueira, M.M., Matos, A.R., 2020 Jul 10. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog. 9 (1), e1004048. https://doi.org/10.1371/journal.ppat.1004048, 24699684.

Elliott, K., Degenhardt, F., Bujanda, L., Buti, M., Alibilee, A., Invernizzi, P., et al., 2020 Jun 15. Genomewide association study of severe COVID-19 related illness and mortality failure. N. Engl. J. Med. 383 (16), 1522–1534. https://doi.org/10.1056/NEJMc2002823, 32558485.

Everitt, A.R., Clare, S., Fertel, J., John, S.P., Wash, R.S., Smith, S.E., et al., 2020 Mar 25. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484 (7395), 519–523. https://doi.org/10.1038/s41586-021-02966-0.

Fricke-Galindo, I., Falcó, M., Bujanda, L., Buti, M., Zepp, C., Invernizzi, P., et al., 2020 May 16. SARS-CoV-2 infection in elderly people: high frequency of ACE2 receptor and IFITM3 restriction. Lancet Infect. Dis. 20 (11), 1775–1786. https://doi.org/10.1016/S1473-3099(20)30283-8, 32804212.

Lee, N., Cao, B., Ke, C., Liu, H., Hu, Y., Tam, C.H.T., et al., 2017 Jul 1. IFITM3, TLR3, and CD55 gene SNPs and cumulative genetic risks for severe outcomes in Chinese patients with SARS-CoV-2 infection. Cell Host Microbe 16 (6), 736–747. https://doi.org/10.1016/j.chom.2017.03.017, 27351739.

Ferreira, J.M., Chin, C.R., Feeley, E.M., Brass, A.L., 2013 Dec 13. IFITMs restrict the replication of multiple pathogenic viruses. J. Mol. Biol. 425 (24), 4937–4955. https://doi.org/10.1016/j.jmb.2013.09.024, 24076421.
Prabhu, S.S., Chakraborty, T.T., Kumar, N., Banerjee, I., 2018 Oct 20. Association between IFITM3 rs12252 polymorphism and influenza susceptibility and severity: a meta-analysis. Gene 674, 70–79. https://doi.org/10.1016/j.gene.2018.06.070, 29940276.

Prelli Bozzo, C., Nchioua, R., Volcic, M., Koecke, L., Krüger, J., Schütz, D., et al., 2021 Jul 28. IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro. Nat. Commun. 12 (1), 4884. https://doi.org/10.1038/s41467-021-24817-y, 34321474.

Qin, L., Wang, D., Li, D., Zhao, Y., Peng, Y., Wellington, D., et al., 2018 May 15. High level antibody response to pandemic influenza H1N1/09 virus is associated with interferon-induced transmembrane protein-3 rs12252-CC in young adults. Front. Cell Infect. Microbiol. 8, 134. https://doi.org/10.3389/fcimb.2018.00134, 29868492.

Randolph, A.G., Yip, W.K., Allen, E.K., Rosenberger, C.M., Agan, A.A., Ash, S.A., et al., 2017 Jul 1. Evaluation of IFITM3 rs12252 association with severe pediatric influenza infection. J. Infect. Dis. 216 (1), 14–21. https://doi.org/10.1093/infdis/jix242, 28531322.

Ren, L., Du, S., Xu, W., Li, T., Wu, S., Jin, N., Li, C., 2020 Nov 30. Current progress on host antiviral factor IFITMs. Front. Immunol. 11, 543444. https://doi.org/10.3389/fimmu.2020.543444, 33329509.

Schönfelder, K., Breuckmann, K., Elsner, C., Dittner, U., Fistera, D., Herbstreit, F., et al., 2021 Jun. The influence of IFITM3 polymorphisms on susceptibility to SARS-CoV-2 infection and severity of COVID-19. Cytokine 142, 155492. https://doi.org/10.1016/j.cyto.2021.155492, 33711707.

Shi, G., Kenney, A.D., Kudryashova, E., Zani, A., Zhang, L., Li, D.A., et al., 2021 Feb 1. Opposing activities of IFITM proteins in SARS-CoV-2 infection. EMBO J. 40 (3), e106501. https://doi.org/10.15252/embj.2020106501, 33270927.

Smith, S.E., Busse, D.C., Binter, S., Weston, S., Diaz Soria, C., Laksono, B.M., et al., 2019 Mar 5. Interferon-induced transmembrane protein 1 restricts replication of viruses that enter cells via the plasma membrane. J. Virol. 93 (6). https://doi.org/10.1128/JVI.01328-10. Epub 2010 Oct 13, 20943977.

Weidner, J.M., Jiang, D., Pan, X.B., Chang, J., Block, T.M., Guo, J.T., 2010 Dec. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J. Virol. 84 (24), 12646–12657. https://doi.org/10.1128/JVI.01328-10. Epub 2010 Oct 13, 20943977.

Wrench, F., Winkler, M., Pohlmann, S., 2014 Sep 26. IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterol-independent mechanisms. Viruses 6 (9), 3683–3698. https://doi.org/10.3390/v6093683, 25256397.

Zhang, Y., Makvandi-Nejad, S., Qin, L., Zhao, Y., Zhang, T., Wang, L., et al., 2015. Interferon-induced transmembrane protein-3 rs12252-C is associated with rapid progression of acute HIV-1 infection in Chinese MSM cohort. AIDS 29, 889–894.

Zhang, Y.H., Zhao, Y., Li, N., Peng, Y.C., Giannoulatou, E., Jin, R.H., et al., 2013. Interferon-induced transmembrane protein-3 rs12252-C is associated with severity in coronavirus disease 2019. J. Infect. Dis. 222 (1), 34–37. https://doi.org/10.1093/infdis/jiaa224, 32348495.